BFS
ALNY icon

Bare Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bare Financial Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602 Sell
2
-4
-67% -$1.21K ﹤0.01% 1593
2026
Q1 		$1.99K Buy
6
+5
+500% +$1.7K ﹤0.01% 987
2025
Q4 		$398 Sell
1
-2
-67% -$885 ﹤0.01% 1498
2025
Q3 		$1.37K Buy
+3
New +$1.22K ﹤0.01% 928

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bare Financial Services's ALNY Position: Q2 2026 in Review

Bare Financial Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 67% in Q2 2026, selling an estimated $1.21K and leaving 2 shares worth $602. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Bare Financial Services first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.99K in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bare Financial Services held 2 shares of Alnylam Pharmaceuticals worth $602 as of Q2 2026.
  • Bare Financial Services sold 4 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.21K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1593 holding.
  • Bare Financial Services first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Bare Financial Services's Alnylam Pharmaceuticals position peaked at $1.99K in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.